# Intra-Cellular Therapies, Inc. – Consensus ‘buy’ rating and 58.3% Upside Potential

- Link: https://www.directorstalkinterviews.com/intra-cellular-therapies-inc.consensus-buy-rating-and-58.3-upside-potential/4121130964
- Published: 2023-10-26T13:31:45+01:00
- Author: Charlotte Edwards

**Intra-Cellular Therapies, Inc.** with ticker code (ITCI) now have 12 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between 100 and 59 calculating the average target price we
see $77.83. Given that the stocks previous close was at $49.17 and the analysts 
are correct then we can expect a percentage increase in value of 58.3%. Also worth
taking note is the 50 day moving average now sits at $54.16 while the 200 day moving
average is $56.03. The total market capitalization for the company now stands at
4.65B. The stock price is currently at: 48.4 USD

 The potential market cap would be $7,361,691,359 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 3.85 and
a -16.27% return on assets.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused
on the discovery, clinical development and commercialization of small molecule drugs
that address underserved medical needs primarily in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within the central nervous
system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes
associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy
and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 
mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled
bipolar depression studies, which evaluated the effects of CAPLYTA on depression
in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study
404) and as adjunctive therapy with lithium or valproate (Study 402).

Share on: